articleTop 1% cited

Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

Nature Medicine · 1999 · Vol. 5(2) · pp. 157–163

Henning Walczak✉(IDEX Corporation (United States))Robert E. Miller(IDEX Corporation (United States))K. Ariail(IDEX Corporation (United States))Brian Gliniak(IDEX Corporation (United States))Thomas S. Griffith(IDEX Corporation (United States))Marek Kubin(IDEX Corporation (United States))W Chin(IDEX Corporation (United States))Jon Jones(IDEX Corporation (United States))Anne Woodward(IDEX Corporation (United States))Tiep Le(IDEX Corporation (United States))Craig A. Smith(IDEX Corporation (United States))Pam Smolak(IDEX Corporation (United States))Raymond G. Goodwin(IDEX Corporation (United States))Charles T. Rauch(IDEX Corporation (United States))JoAnn C. L. Schuh(IDEX Corporation (United States))David H. Lynch(IDEX Corporation (United States))

View via DOI Publisher page

Cell death mechanisms and regulation RNA Interference and Gene Delivery NF-κB Signaling PathwaysIn vivoApoptosisNecrosisTumor necrosis factor alphaCancer researchIn vitroFas ligandProgrammed cell deathBiologyChemistry

MeSH terms

AnimalsAntineoplastic AgentsDose-Response Relationship, DrugHumansMembrane GlycoproteinsMice, Inbred BALB CMice, Inbred C57BLProtein ConformationTumor Cells, CulturedTumor Necrosis Factor-alphaMice, SCIDApoptosisApoptosis Regulatory ProteinsMiceTNF-Related Apoptosis-Inducing Ligand

Citations

2,493

FWCI

42.97

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems